MedTrace Logo

Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy

NCT00242606 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 409

Last updated 2012-05-09

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy, safety and tolerance of the drugs Lamotrigine and Levetiracetam in the initial monotherapy of patients with newly diagnosed epilepsy.

Conditions

Interventions

DRUG

Lamotrigine

titrate to 200mg over 10 weeks and maintained until end of week 26

DRUG

Levetiracetam

titrate to 2000mg/day over 22 days, maintain until the end of week 26

Sponsors & Collaborators

  • UCB Pharma GmbH

    collaborator INDUSTRY

  • Philipps University Marburg

    lead OTHER

Principal Investigators

  • Felix Rosenow, M.D. · Philipps University Marburg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2008-06-30
Completion
2009-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00242606 on ClinicalTrials.gov